The Use of Trientine in Preventing the Effects of Interrupting Penicillamine Therapy in Wilson's Disease
- 23 July 1987
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 317 (4), 209-213
- https://doi.org/10.1056/nejm198707233170405
Abstract
Penicillamine is known to be effective therapy for Wilson's disease. However, the clinical consequences of the abrupt and permanent withdrawal of penicillamine have not been investigated.Keywords
This publication has 13 references indexed in Scilit:
- Fulminant Wilson's disease treated with postdilution hemofiltration and orthotopic liver transplantationGastroenterology, 1986
- Wilson's Disease: Indications for Liver TransplantsHepatology, 1984
- Oral Zinc Therapy for Wilson's DiseaseAnnals of Internal Medicine, 1983
- TREATMENT OF WILSON'S DISEASE WITH TRIENTINE (TRIETHYLENE TETRAMINE) DIHYDROCHLORIDEThe Lancet, 1982
- Pemphigus-like mucosal lesions: A side effect of penicillamine therapyOral Surgery, Oral Medicine, Oral Pathology, 1981
- Treatment of Wilson's Disease with Triethylene Tetramine DihydrochlorideDevelopmental Pharmacology and Therapeutics, 1980
- TRIETHYLENE TETRAMINE DIHYDROCHLORIDE IN WILSON'S DISEASEThe Lancet, 1970
- MANAGEMENT OF PENICILLAMINE NEPHROPATHY IN WILSON'S DISEASE: A NEW CHELATING AGENTThe Lancet, 1969
- Prevention of Wilson's Disease in Asymptomatic PatientsNew England Journal of Medicine, 1968
- Penicillamine, a new oral therapy for Wilson's diseaseAmerican Journal Of Medicine, 1956